Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Belle Health vs Mint Med

Belle Health
Graded #77

Lower grade

vs+4.9
Mint Med
Graded #46

Higher grade

The verdict

Mint Med takes it — 78.7/100 to 73.8/100.

Mint Med grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Low both-molecule pricing ($117/$159) and verified — but only 36 states.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueBelle Health +2
92
90
Dose & formulationMint Med +8
72
80
Clinical oversightEven
55
55
Labs & monitoringMint Med +11
72
83
FulfillmentBelle Health +3
85
82
Contract termsMint Med +31
55
86
Belle Health · left barMint Med · right bar

The numbers

MetricBelle HealthMint Med
WeighScore73.8/10078.7/100
GradeCC+
Scorecard rank#77#46
Semaglutide$119/mo$117/mo
Tirzepatide$199/mo (all doses, 3-month plan, compounded)$159/mo
CoverageAll 50 states36 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Belle Health

Graded #77 · C

FDAWarning letter issued to Belle Health LLC dba Belle in February 2026. See the FDA warning-letter database.

Strengths

  • Five named compounding pharmacy partners disclosed (Striker, Strive, OptioRx, Enovex, Braun PharmaCare)
  • Flat-rate pricing — $119/mo semaglutide, $199/mo tirzepatide — doesn't rise at higher doses
  • Free weekly registered-dietitian sessions included
  • Operating since 2017
  • LegitScript Certified

Where it loses points

  • $199 tirzepatide price requires a 3-month bundle commitment
  • Compounded medications are not FDA-approved
  • Multi-pharmacy model — formulations may differ across orders
  • FDA issued Belle Health LLC dba Belle a warning letter in February 2026; the letter is public in FDA's warning-letter database
Mint Med

Graded #46 · C+

FDAWarning letter issued to Glow Medispa, LLC dba Mint Med in June 2026. See the FDA warning-letter database.

Strengths

  • $117 sema / $159 tirz
  • LegitScript-verified
  • Both molecules

Where it loses points

  • Only 36 states
  • Injection-only
  • Monitoring detail sparse

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 544 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard